We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TYRUKO (Sandoz Pty Ltd)
Product name
TYRUKO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
158 (175 working days)
Active ingredients
Natalizumab
Registration type
New biosimilar medicine
Indication
TYRUKO is indicated as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (MS) to delay the progression of physical disability and to reduce the frequency of relapse.